2025-05-22-Jefferies-邀请OMass_Therapeutics纽约非交易路演及团体午餐-_6月26日_星期四_6页_244kb

Event: OMass Therapeutics is hosting an in-person meeting and group lunch in NYC on Thursday, June 26, 2025, for equity research opportunities. This includes one-on-one interviews and a group session.

Company Background: OMass Therapeutics is a private biotech firm focusing on oral drugs for rare diseases. Its lead asset is an ACTH receptor antagonist for Congenital Adrenal Hyperplasia (CAH), potentially more potent than competitor atumelnant. The company may enter Phase I clinical trials in late 2025, with additional preclinical assets targeting conditions like IBD, lupus, and immunology.

Management: Key attendees include CEO Ros Deegan and VP of Clinical Development Steve Griffen.

Registration: Interested parties should contact their sales representative to secure a spot for the 1x1 meetings or group lunch.

Disclosure: The report emphasizes compliance with financial regulations, potential conflicts of interest, and standard equity research disclaimers, including analyst certifications and risk factors under US securities laws.